Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Non-Current Liabilities (2016 - 2025)

Cumberland Pharmaceuticals' Total Non-Current Liabilities history spans 16 years, with the latest figure at $46.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 0.6% year-over-year to $46.5 million; the TTM value through Dec 2025 reached $46.5 million, down 0.6%, while the annual FY2025 figure was $46.5 million, 0.6% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $46.5 million at Cumberland Pharmaceuticals, up from $34.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $49.4 million in Q4 2022 and bottomed at $33.2 million in Q2 2021.
  • The 5-year median for Total Non-Current Liabilities is $44.6 million (2022), against an average of $41.8 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 43.64% in 2022 before it fell 26.16% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $34.4 million in 2021, then surged by 43.64% to $49.4 million in 2022, then fell by 7.55% to $45.6 million in 2023, then increased by 2.4% to $46.7 million in 2024, then fell by 0.6% to $46.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Total Non-Current Liabilities are $46.5 million (Q4 2025), $34.1 million (Q3 2025), and $33.9 million (Q2 2025).